Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3164611 | 0.83 | MAPT (0.57) | MAPTLMNAMEN1KMT2ATSHR | |
| SCHEMBL29703894 | 0.83 | MAPT (0.57) | MAPTLMNAMEN1KMT2ATSHR | |
| SCHEMBL264644 | 0.82 | XDH (0.51) | MAPTLMNAMEN1KMT2AXDH | |
| SCHEMBL25410350 | 0.81 | LMNA (0.36) | CYP19A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL2738746 | 0.75 | CYP3A4 (0.47) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5311953 | 0.74 | MAPT (0.60) | MAPTLMNAMEN1KMT2AXDH | |
| SCHEMBL7370507 | 0.74 | TTR (0.46) | MAPTMEN1KMT2AXDHALDH1A1 | |
| SCHEMBL12497469 | 0.73 | ALDH1A1 (0.43) | MAPTLMNAMEN1KMT2AXDH | |
| SCHEMBL31377032 | 0.72 | KDM4E (0.49) | MAPTLMNAMEN1KMT2ATSHR | |
| SCHEMBL7207777 | 0.72 | TDP1 (0.45) | MAPTLMNAMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300418-A1 | Synthesis of Cardiolipin Analogues and Uses Thereof | AHMAD MOGHIS U | 2008-12-04 | — | — | US | claimed |
| EP-1996947-A1 | METHOD FOR FORMING MOLECULAR SEQUENCES ON SURFACES | The Regents of the University of Michigan (US) | 2008-12-03 | — | — | EP | claimed |
| WO-2008118167-A1 | METHOD FOR FORMING MOLECULAR SEQUENCES ON SURFACES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-02 | — | — | WO | claimed |
| US-20070224616-A1 | METHOD FOR FORMING MOLECULAR SEQUENCES ON SURFACES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-09-27 | — | — | US | claimed |
| EP-1819715-A2 | SYNTHESIS OF CARDIOLIPIN ANALOGUES AND USES THEREOF | Neopharm, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006052906-A2 | SYNTHESIS OF CARDIOLIPIN ANALOGUES AND USES THEREOF | NEOPHARM, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | NEOPHARM, INC. (US) | 2005-12-01 | — | — | US | claimed |
| EP-1556392-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | Neopharm, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004039817-A9 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM INC (US) | 2004-07-22 | — | — | WO | claimed |
| WO-2004039817-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM, INC. (US) | 2004-05-13 | — | — | WO | claimed |
| WO-2016091228-A1 | SUBSTITUTED PHENYLTETRAZOLE, ITS USE AND PHARMACEUTICAL PREPARATION CONTAINING IT | UNIVERZITA KARLOVA V PRAZE (CZ) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016091228-A1 | SUBSTITUTED PHENYLTETRAZOLE, ITS USE AND PHARMACEUTICAL PREPARATION CONTAINING IT | UNIVERZITA KARLOVA V PRAZE (CZ) | 2016-06-16 | — | — | WO | disclosed |
| US-20080300418-A1 | Synthesis of Cardiolipin Analogues and Uses Thereof | AHMAD MOGHIS U | 2008-12-04 | — | — | US | disclosed |
| EP-1996947-A1 | METHOD FOR FORMING MOLECULAR SEQUENCES ON SURFACES | The Regents of the University of Michigan (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008118167-A1 | METHOD FOR FORMING MOLECULAR SEQUENCES ON SURFACES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2004039817-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM, INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-0739898-B1 | Phosphonomonoester nucleic acids, methods for their preparation and their use | AVENTIS PHARMA GMBH (DE) | 2001-09-26 | — | — | EP | disclosed |
| US-6127346-A | FOR THE TREATMENT OF VIRUSES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-10-03 | — | — | US | disclosed |
| US-5874553-A | ANTIBODIES; INHIBITOR OF GENE EXPRESSION | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-23 | — | — | US | disclosed |
| EP-0739898-A2 | Phosphonomonoester nucleic acids, methods for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | PHOSPHO1, MGLL, LIPA | CYP19A1 3639/4885MAPT 4872/4885LMNA 1174/4885 |
| US-20080300418-A1 | Synthesis of Cardiolipin Analogues and Uses Thereof | PHOSPHO1, SGMS1, SGMS2 | CYP19A1 3823/4885MAPT 4791/4885LMNA 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.